Overview

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 32 weeks in approximately 140 adult participants with active Systemic Lupus Erythematosus (SLE).
Phase:
Phase 2
Details
Lead Sponsor:
Galapagos NV